Effect of sustained intensive therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis: a 5-year real-world consecutive study
Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects over 1% of the global population, causing painful joint inflammation, cartilage damage, and long-term disability. For decades, clinicians have focused on moving beyond symptom relief to achieve remission—a state where inflammation, pain, and disease progression nearly stop. Now, a 5-year real-world study from Chinese researchers offers critical insights into how “sustained intensive therapy” with disease-modifying anti-rheumatic drugs (DMARDs) can help patients stay in remission longer.
What the Study Did
Researchers from Peking University People’s Hospital, Peking University Shenzhen Hospital, and Peking University International Hospital followed 541 adults with active RA from 2012 to 2017. Patients were divided into three groups based on their treatment:
- Sustained Intensive Therapy (SUIT): 207 patients who stayed on a consistent regimen of DMARDs (e.g., methotrexate, leflunomide, hydroxychloroquine) plus possible steroids or biologic drugs.
- Intermittent Intensive Therapy (Int-SUIT): 182 patients who started intensive therapy but tapered or stopped drugs once symptoms improved.
- Non-Intensive Therapy (non-SUIT): 152 patients on standard, less aggressive DMARD regimens.
Remission was measured using three validated criteria:
- DAS28-ESR/CRP: Scores combining joint pain, swelling, and inflammation markers (erythrocyte sedimentation rate, or ESR; C-reactive protein, or CRP). A score ≤2.6 indicates remission.
- Clinical Deep Remission (CliDR): A stricter standard requiring no swollen/tender joints and normal ESR/CRP levels (a sign of no systemic inflammation).
Key Results: Sustained Therapy Beats Intermittent or Non-Intensive Care
The findings, published in the Chinese Medical Journal, showed that sticking to intensive therapy long-term drastically improved remission rates:
- 5-Year Remission Rates: Only 5.6% of SUIT patients maintained remission (DAS28-ESR) after 5 years—compared to 0.3% of non-SUIT patients and 0.8% of Int-SUIT patients.
- Cumulative Remission: Over 5 years, SUIT patients had a 39.7% cumulative remission rate (DAS28-ESR)—twice as high as non-SUIT patients (19.5%). Using the stricter CliDR criteria, SUIT patients had a 24.5% cumulative remission rate—nearly three times higher than non-SUIT patients (8.7%).
- Predictors of Success: Younger age and adherence to the SUIT regimen were the strongest predictors of long-term remission. Higher initial inflammation (ESR) and more swollen joints at baseline made remission harder to maintain.
What This Means for RA Patients and Doctors
For patients, the takeaway is clear: consistency matters. Many RA patients worry about DMARD side effects (e.g., liver toxicity, lung issues) and stop taking their meds too soon—only to experience relapses. This study shows that “tight control” (keeping disease activity low) through sustained intensive therapy is the best way to make remission last.
For doctors, the study supports the “treat-to-target” strategy—where treatment is adjusted to keep RA activity as low as possible. The European League Against Rheumatism (EULAR) already recommends tapering DMARDs if a patient is in persistent remission, but this research highlights that sustaining intensive therapy first is critical to long-term success.
The Road Ahead
While the study confirms the value of sustained intensive therapy, questions remain: How long do patients need to stay on intensive therapy before tapering? Can older patients (who are more likely to stop therapy due to side effects) still benefit from SUIT? More research is needed to personalize treatment, but the data is clear: for many RA patients, staying the course with intensive therapy is worth it.
The original study was conducted by Yue-Ming Cai, Ru Li, and colleagues from the Department of Rheumatology and Immunology at Peking University People’s Hospital, Peking University Shenzhen Hospital, and Peking University International Hospital. It was published in the Chinese Medical Journal in 2020.
doi:10.1097/CM9.0000000000000811
Was this helpful?
0 / 0